XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease with secondary programs focused on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.



Press Releases

XORTX Receives FDA Response on Orphan Drug Designation Application

CALGARY, Alberta, Nov. 26, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has received a response ...
Read More

Investor Relations

Fact Sheet

Presentation

Read More